[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Silence Therapeutics Plc ADR (SLN)

Silence Therapeutics Plc ADR (SLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 814,628
  • Shares Outstanding, K 60,209
  • Annual Sales, $ 560 K
  • Annual Income, $ -88,610 K
  • EBIT $ -78 M
  • EBITDA $ -78 M
  • 60-Month Beta 1.39
  • Price/Sales 1,472.37
  • Price/Cash Flow N/A
  • Price/Book 16.78

Options Overview Details

View History
  • Implied Volatility 88.97% (+64.32%)
  • Historical Volatility 99.21%
  • IV Percentile 14%
  • IV Rank 5.89%
  • IV High 1,116.93% on 03/30/26
  • IV Low 24.65% on 08/26/26
  • Expected Move (DTE 22) 0.37 (2.78%)
  • Put/Call Vol Ratio 1.51
  • Today's Volume 93
  • Volume Avg (30-Day) 3,015
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 44,297
  • Open Int (30-Day) 31,990
  • Expected Range 13.08 to 13.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.26
  • Number of Estimates 3
  • High Estimate $-0.24
  • Low Estimate $-0.27
  • Prior Year $-0.45
  • Growth Rate Est. (year over year) +42.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.32 +30.33%
on 08/03/26
17.58 -23.47%
on 08/10/26
+1.38 (+11.43%)
since 07/27/26
3-Month
5.88 +128.74%
on 06/09/26
17.58 -23.47%
on 08/10/26
+6.65 (+97.79%)
since 05/27/26
52-Week
4.19 +221.00%
on 02/12/26
17.58 -23.47%
on 08/10/26
+8.25 (+158.65%)
since 08/27/25

Most Recent Stories

More News
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced...

SLN : 13.45 (-0.59%)
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has...

SLN : 13.45 (-0.59%)
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has...

SLN : 13.45 (-0.59%)
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% ...

SLN : 13.45 (-0.59%)
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter...

SLN : 13.45 (-0.59%)
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results...

SLN : 13.45 (-0.59%)
Silence Therapeutics reports tomorrow with August trial data looming larger than the quarter itself

Barchart Research What to Expect from SLN Earnings SLN Generated August 5, 2026 Current Price $11.24 EPS Estimate $$-0.32 Consensus Rating Moderate Buy Average Move 5.76% Silence Therapeutics reports tomorrow...

SLN : 13.45 (-0.59%)
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy...

SLN : 13.45 (-0.59%)
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led...

SLN : 13.45 (-0.59%)
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence...

SLN : 13.45 (-0.59%)

Business Summary

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease...

See More

Key Turning Points

3rd Resistance Point 13.96
2nd Resistance Point 13.82
1st Resistance Point 13.64
Last Price 13.45
1st Support Level 13.31
2nd Support Level 13.17
3rd Support Level 12.99

See More

52-Week High 17.58
Last Price 13.45
Fibonacci 61.8% 12.46
Fibonacci 50% 10.88
Fibonacci 38.2% 9.30
52-Week Low 4.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.